Rockwell Medical Q2 sales rise 11% on new customers
RMTI•Outlook
- Rockwell Medical sees 2026 net sales of $70 mln to $75 mln
- Company expects 2026 gross margin of 18% to 22%
- Rockwell Medical forecasts 2026 adjusted EBITDA of $1 mln to $2 mln
Overview
- Hemodialysis products maker's Q2 net sales rose 11% yr/yr, driven by new customer growth
- Gross profit up 30% yr/yr as gross margin expands to 18% on lower manufacturing costs, higher volume
- Company completed 1-for-10 reverse stock split in July to regain Nasdaq compliance
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Sales | Slight Miss* | $17.80 mln | $17.84 mln (2 Analysts) |
| Q2 Loss Per Share | $0.34 | ||
| Q2 Net Loss | $1.20 mln | ||
| Q2 Gross Profit | $3.20 mln | ||
| Q2 Operating Income | -$1.10 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell". The average consensus recommendation for the pharmaceuticals peer group is "buy". Wall Street's median 12-month price target for Rockwell Medical Inc is $30.00, about 299.5% above its August 12 closing price of $7.51.
